---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-009748"
form_type: "8-K"
ticker: "GYRE"
cik: "0001124105"
company_name: "GYRE THERAPEUTICS, INC."
filed_at: "2023-03-02T23:59:59+00:00"
generated_at: "2026-06-18T14:11:19.383454+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Catalyst sells rare bleeding disorder assets to GC Biopharma for $6M; GNI revenue $102M

## Summary
- Sold MarzAA, DalcA, and CB-2679d-GT to GC Biopharma for $6M total ($1M upfront, $5M holdback due Feb 2025).
- Net proceeds from sale to be distributed to holders of contingent value rights issued to stockholders of record Jan 5, 2023.
- GNI Group reported FY2022 revenue ~$102M and net profit ~$23M from pirfenidone sales in China for IPF.
- GNI Transactions (purchase of F351 assets and controlling interest in Beijing Continent) remain pending.

## SEC filing metadata
- accession: 0001140361-23-009748
- form_type: 8-K
- ticker: GYRE
- cik: 0001124105
- company_name: GYRE THERAPEUTICS, INC.
- filed_at: 2023-03-02T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124105/000114036123009748/0001140361-23-009748-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124105/000114036123009748/brhc10049211_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-009748
- JSON: https://secwatch.observer/filing/0001140361-23-009748.json
- Plain text: https://secwatch.observer/filing/0001140361-23-009748.txt

## Key facts
- M&A Transactions
  GYRE THERAPEUTICS, INC. completed a disposition involving GC Biopharma Corp. for $6 million in cash (closed 2023-02-27).
  - Action: disposition
  - Counterparty: GC Biopharma Corp.
  - Consideration: $6 million in cash
  - Closing: 2023-02-27
  source text: (MarzAA), dalcinonacog alpha (DalcA) and CB-2679d-GT (the “Purchased Assets”). In consideration for the purchase of the Purchased Assets, Buyer will pay Catalyst a total of $6 million in cash, with $1 million payable on closing and $5 million retained as a hold-back until twenty-four months after the closing, subject to the satisfaction of post-closing
  evidence_url: https://www.sec.gov/Archives/edgar/data/1124105/000114036123009748/0001140361-23-009748-index.htm
- Material Agreements
  GYRE THERAPEUTICS, INC. entered into Purchase Agreement with GC Biopharma Corp. valued at $6 million in cash, with $1 million payable on closing and $5 million retained as a hold-back (effective 2023-02-27).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: GC Biopharma Corp.
  - Value: $6 million in cash, with $1 million payable on closing and $5 million retained as a hold-back
  - Effective: 2023-02-27
  source text: On February 27, 2023, Catalyst Biosciences, Inc. (“Catalyst”) entered into and closed on an Asset Purchase Agreement (the “Purchase Agreement”) with GC Biopharma Corp. (“Buyer”), pursuant to which Buyer acquired on such date Catalyst’s legacy rare bleeding disorder program, including marzeptacog alpha activated (MarZAA), dalcinonacog alpha (DalcA) and CB-2679d-GT (the “Purchased Assets”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1124105/000114036123009748/0001140361-23-009748-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.